NCT06927739 - Focused Orticumab Research for Treating Inflammation in Coronary Arteries | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

February 8, 2027

Study Completion Date

June 1, 2027

Conditions

Acute Coronary SyndromesCoronary Arterial Disease (CAD)InflammationHeart DiseaseMyocardial InfarctAtherosclerotic Coronary Vascular Disease

Interventions

DRUG

Orticumab

Orticumab treatment for 24 weeks for post MI population

DRUG

Placebo

Placebo for 24 weeks for the post MI population

Trial Locations (7)

RECRUITING

Abcentra Investigational Site, Baltimore

RECRUITING

Abcentra Investigational Site, Boca Raton

NOT_YET_RECRUITING

Abcentra Investigational Site, Louisville

RECRUITING

Abcentra Investigational Site, Richmond

RECRUITING

Abcentra Investigational Site, Midland

NOT_YET_RECRUITING

Abcentra Investigational Site, Los Angeles

RECRUITING

Abcentra Investigational Site, Torrance